ARVN

Arvinas, Inc.
CAPPED RATING

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Arvinas, Inc. (ARVN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B
Factor Score 3.2 / 5.0
Growth
F
Factor Score 0.2 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.1
EV / EBITDA 4.3
Rev Growth YoY -98.8%
Gross Margin 96.7%
Price Return 3M -26.9%
Price Return 12M -33.1%
Catalyst Signal 0.00
Market Cap $443.3M
TTM Revenue $275.3M
Price / Sales 1.6
ROE -1.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.2) F (0.2) B- (3.1) C- (2.0) C+ (2.6) C (2.2)
2026-11-10 B (3.3) F (0.2) B- (3.1) C- (2.1) C+ (2.6) C (2.3)
2026-11-03 B- (3.1) F (0.3) B- (3.1) C- (2.0) F (0.0) D+ (1.7)
2026-10-27 B- (3.1) F (0.3) B- (3.1) C- (2.1) F (0.0) D+ (1.7)
2026-10-20 B- (3.1) F (0.3) B- (3.1) C- (2.1) F (0.0) D+ (1.7)
Page 1 of 7